(3R,5S)-3,5-dimethylpiperidine-1-carbonyl chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,5S)-3,5-dimethylpiperidine-1-carbonyl chloride
• 英文别名: (3S,5R)-3,5-dimethylpiperidine-1-carbonyl chloride
• 化学式: C₈H₁₄ClNO
• 分子量: 175.658
• InChiKey: XKWWTGFKHIQSCM-KNVOCYPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3R,5S)-3,5-dimethylpiperidine-1-carbonyl chloride 在 盐酸 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-((3S,5R)-3,5-dimethylpiperidine-1-carbonyl)-N-(7-methoxy-1H-benzo[d]imidazol-2-yl)hydrazinecarbothioamide
  参考文献：
  名称：

  [EN] IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS
  [FR] DÉRIVÉS D'IMIDAZOPYRIDINE ET D'OXAZOLOPYRIDINE ET LEURS ANALOGUES, LEURS PROCÉDÉS DE PRÉPARATION, PROCÉDÉS D'INHIBITION DE LA VOIE HIF-1/2A ET INDUCTION DE LA FERROPTOSE

  摘要：

  Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-1α and HIF-2α and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-1/2α or iron metabolism.

  公开号：

  WO2023234970A1
• 作为产物：
  描述：

  (3S,5R)-3,5-dimethylpiperidine 在 吡啶 、 均苯三甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 (3R,5S)-3,5-dimethylpiperidine-1-carbonyl chloride
  参考文献：
  名称：

  [EN] IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS
  [FR] DÉRIVÉS D'IMIDAZOPYRIDINE ET D'OXAZOLOPYRIDINE ET LEURS ANALOGUES, LEURS PROCÉDÉS DE PRÉPARATION, PROCÉDÉS D'INHIBITION DE LA VOIE HIF-1/2A ET INDUCTION DE LA FERROPTOSE

  摘要：

  Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-1α and HIF-2α and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-1/2α or iron metabolism.

  公开号：

  WO2023234970A1

文献信息

• SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF
  申请人：Impact Therapeutics (Shanghai), Inc

  公开号：EP3567041A9

  公开（公告）日：2022-04-20

  The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A4, B1-B3, D1-D4 and R1-R3 are defined herein. Compounds having Formula I are kinalse inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

  本公开涉及取代的融合杂芳香化合物及其用途。具体而言，本公开提供了以下式I的化合物： 或其药用可接受的盐或前药，其中A1-A4、B1-B3、D1-D4和R1-R3如本文所述定义。具有式I的化合物是激酶抑制剂。因此，本公开的化合物可用于治疗由DDR功能缺陷引起的临床状况，如癌症。
• Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US10874670B2

  公开（公告）日：2020-12-29

  The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A4, B1-B3, D1-D4 and R1-R3 are defined herein. Compounds having Formula I are kinalse inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

  本公开涉及取代的融合杂芳香族化合物及其用途。具体地说，本公开提供了如下式 I 的化合物： 或其药学上可接受的盐或原药，其中 A1-A4、B1-B3、D1-D4 和 R1-R3 在本文中定义。具有式 I 的化合物是 Kinalse 抑制剂。因此，本公开的化合物可用于治疗由 DDR 功能缺陷引起的临床病症，如癌症。